Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) Stock Competitors & Peer Comparison
See LGND's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for LGND and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| LGND | $287.54 | -2.95% | 5.8B | 34.48 | $8.34 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
LGND vs VRTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas VRTX's P/E ratio is 25.35. In terms of profitability, LGND's ROE is +0.16%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, LGND is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
LGND vs REGN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas REGN's P/E ratio is 16.71. In terms of profitability, LGND's ROE is +0.16%, compared to REGN's ROE of +0.18%. Regarding short-term risk, LGND is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for LGND.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
LGND vs VRNA Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas VRNA's P/E ratio is -102.80. In terms of profitability, LGND's ROE is +0.16%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, LGND is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for LGND.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
LGND vs ARGX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ARGX's P/E ratio is 78.75. In terms of profitability, LGND's ROE is +0.16%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, LGND is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
LGND vs SGEN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas SGEN's P/E ratio is -57.19. In terms of profitability, LGND's ROE is +0.16%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, LGND is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
LGND vs RVMDW Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, LGND's ROE is +0.16%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, LGND is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
LGND vs RVMD Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RVMD's P/E ratio is -26.52. In terms of profitability, LGND's ROE is +0.16%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, LGND is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
LGND vs ONC Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ONC's P/E ratio is 70.70. In terms of profitability, LGND's ROE is +0.16%, compared to ONC's ROE of +0.12%. Regarding short-term risk, LGND is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
LGND vs ALNY Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ALNY's P/E ratio is 37.02. In terms of profitability, LGND's ROE is +0.16%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, LGND is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
LGND vs ROIV Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ROIV's P/E ratio is -34.86. In terms of profitability, LGND's ROE is +0.16%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, LGND is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
LGND vs INCY Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas INCY's P/E ratio is 16.06. In terms of profitability, LGND's ROE is +0.16%, compared to INCY's ROE of +0.30%. Regarding short-term risk, LGND is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for LGND.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
LGND vs BNTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BNTX's P/E ratio is -19.61. In terms of profitability, LGND's ROE is +0.16%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, LGND is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
LGND vs UTHR Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas UTHR's P/E ratio is 19.10. In terms of profitability, LGND's ROE is +0.16%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, LGND is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for LGND.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
LGND vs MRNA Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MRNA's P/E ratio is -6.73. In terms of profitability, LGND's ROE is +0.16%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, LGND is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for LGND.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
LGND vs INSM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas INSM's P/E ratio is -17.15. In terms of profitability, LGND's ROE is +0.16%, compared to INSM's ROE of -1.30%. Regarding short-term risk, LGND is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for LGND.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
LGND vs BGNE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BGNE's P/E ratio is -22.55. In terms of profitability, LGND's ROE is +0.16%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, LGND is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
LGND vs DNA-WT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, LGND's ROE is +0.16%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, LGND is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for LGND.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
LGND vs GMAB Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas GMAB's P/E ratio is 20.77. In terms of profitability, LGND's ROE is +0.16%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, LGND is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for LGND.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
LGND vs NBIX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas NBIX's P/E ratio is 24.10. In terms of profitability, LGND's ROE is +0.16%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, LGND is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
LGND vs JAZZ Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, LGND's ROE is +0.16%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, LGND is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for LGND.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
LGND vs BBIO Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BBIO's P/E ratio is -21.41. In terms of profitability, LGND's ROE is +0.16%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, LGND is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
LGND vs ASND Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ASND's P/E ratio is -100.79. In terms of profitability, LGND's ROE is +0.16%, compared to ASND's ROE of -56.42%. Regarding short-term risk, LGND is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
LGND vs EXEL Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas EXEL's P/E ratio is 15.88. In terms of profitability, LGND's ROE is +0.16%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, LGND is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for LGND.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
LGND vs KRTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas KRTX's P/E ratio is -28.09. In terms of profitability, LGND's ROE is +0.16%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, LGND is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
LGND vs ARWR Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ARWR's P/E ratio is -39.37. In terms of profitability, LGND's ROE is +0.16%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, LGND is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
LGND vs BMRN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BMRN's P/E ratio is 28.86. In terms of profitability, LGND's ROE is +0.16%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, LGND is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
LGND vs TECH Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas TECH's P/E ratio is 37.16. In terms of profitability, LGND's ROE is +0.16%, compared to TECH's ROE of +0.05%. Regarding short-term risk, LGND is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for LGND.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
LGND vs RNAM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RNAM's P/E ratio is -17.39. In terms of profitability, LGND's ROE is +0.16%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, LGND is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
LGND vs AXSM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas AXSM's P/E ratio is -56.92. In terms of profitability, LGND's ROE is +0.16%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, LGND is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for LGND.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
LGND vs MDGL Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MDGL's P/E ratio is -36.51. In terms of profitability, LGND's ROE is +0.16%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, LGND is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for LGND.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
LGND vs SMMT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas SMMT's P/E ratio is -8.14. In terms of profitability, LGND's ROE is +0.16%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, LGND is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for LGND.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
LGND vs KRYS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas KRYS's P/E ratio is 45.60. In terms of profitability, LGND's ROE is +0.16%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, LGND is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for LGND.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
LGND vs HALO Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas HALO's P/E ratio is 17.87. In terms of profitability, LGND's ROE is +0.16%, compared to HALO's ROE of +1.26%. Regarding short-term risk, LGND is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for LGND.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
LGND vs CYTK Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CYTK's P/E ratio is -13.23. In terms of profitability, LGND's ROE is +0.16%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, LGND is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
LGND vs RXDX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RXDX's P/E ratio is -56.47. In terms of profitability, LGND's ROE is +0.16%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, LGND is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
LGND vs ABVX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ABVX's P/E ratio is -65.48. In terms of profitability, LGND's ROE is +0.16%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, LGND is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
LGND vs NUVL Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas NUVL's P/E ratio is -21.79. In terms of profitability, LGND's ROE is +0.16%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, LGND is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for LGND.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
LGND vs CRNX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CRNX's P/E ratio is -16.28. In terms of profitability, LGND's ROE is +0.16%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, LGND is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
LGND vs PTGX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas PTGX's P/E ratio is -75.49. In terms of profitability, LGND's ROE is +0.16%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, LGND is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
LGND vs IMGN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas IMGN's P/E ratio is -111.55. In terms of profitability, LGND's ROE is +0.16%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, LGND is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
LGND vs IONS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas IONS's P/E ratio is -30.10. In terms of profitability, LGND's ROE is +0.16%, compared to IONS's ROE of -1.11%. Regarding short-term risk, LGND is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for LGND.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
LGND vs PRAX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas PRAX's P/E ratio is -23.02. In terms of profitability, LGND's ROE is +0.16%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, LGND is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
LGND vs SYRE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas SYRE's P/E ratio is -47.27. In terms of profitability, LGND's ROE is +0.16%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, LGND is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for LGND.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
LGND vs KYMR Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas KYMR's P/E ratio is -29.29. In terms of profitability, LGND's ROE is +0.16%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, LGND is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for LGND.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
LGND vs ALKS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ALKS's P/E ratio is 52.66. In terms of profitability, LGND's ROE is +0.16%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, LGND is more volatile compared to ALKS. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
LGND vs BPMC Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BPMC's P/E ratio is -51.58. In terms of profitability, LGND's ROE is +0.16%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, LGND is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
LGND vs APGE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas APGE's P/E ratio is -30.97. In terms of profitability, LGND's ROE is +0.16%, compared to APGE's ROE of -0.33%. Regarding short-term risk, LGND is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
LGND vs CERE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CERE's P/E ratio is -16.47. In terms of profitability, LGND's ROE is +0.16%, compared to CERE's ROE of -0.72%. Regarding short-term risk, LGND is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
LGND vs TGTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas TGTX's P/E ratio is 17.88. In terms of profitability, LGND's ROE is +0.16%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, LGND is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
LGND vs IMVT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas IMVT's P/E ratio is -14.46. In terms of profitability, LGND's ROE is +0.16%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, LGND is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for LGND.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
LGND vs PCVX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas PCVX's P/E ratio is -7.86. In terms of profitability, LGND's ROE is +0.16%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, LGND is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
LGND vs IBRX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas IBRX's P/E ratio is -8.44. In terms of profitability, LGND's ROE is +0.16%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, LGND is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
LGND vs MTSR Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MTSR's P/E ratio is -23.58. In terms of profitability, LGND's ROE is +0.16%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, LGND is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for LGND.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
LGND vs MRUS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MRUS's P/E ratio is -17.05. In terms of profitability, LGND's ROE is +0.16%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, LGND is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for LGND.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
LGND vs RYTM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RYTM's P/E ratio is -31.71. In terms of profitability, LGND's ROE is +0.16%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, LGND is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for LGND.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
LGND vs ACLX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ACLX's P/E ratio is -28.27. In terms of profitability, LGND's ROE is +0.16%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, LGND is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
LGND vs COGT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas COGT's P/E ratio is -18.45. In terms of profitability, LGND's ROE is +0.16%, compared to COGT's ROE of -0.83%. Regarding short-term risk, LGND is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for LGND.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
LGND vs RETA Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RETA's P/E ratio is -66.29. In terms of profitability, LGND's ROE is +0.16%, compared to RETA's ROE of +0.47%. Regarding short-term risk, LGND is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
LGND vs MIRM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MIRM's P/E ratio is -7.78. In terms of profitability, LGND's ROE is +0.16%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, LGND is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for LGND.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
LGND vs BLTE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas BLTE's P/E ratio is -84.82. In terms of profitability, LGND's ROE is +0.16%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, LGND is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
LGND vs ERAS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ERAS's P/E ratio is -19.51. In terms of profitability, LGND's ROE is +0.16%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, LGND is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
LGND vs CGON Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CGON's P/E ratio is -30.55. In terms of profitability, LGND's ROE is +0.16%, compared to CGON's ROE of -0.23%. Regarding short-term risk, LGND is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
LGND vs CNTA Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CNTA's P/E ratio is -22.63. In terms of profitability, LGND's ROE is +0.16%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, LGND is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
LGND vs XENE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas XENE's P/E ratio is -13.33. In terms of profitability, LGND's ROE is +0.16%, compared to XENE's ROE of -0.49%. Regarding short-term risk, LGND is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check XENE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
LGND vs SRRK Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas SRRK's P/E ratio is -13.17. In terms of profitability, LGND's ROE is +0.16%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, LGND is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for LGND.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
LGND vs PTCT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas PTCT's P/E ratio is -29.19. In terms of profitability, LGND's ROE is +0.16%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, LGND is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for LGND.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
LGND vs CDTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CDTX's P/E ratio is -19.77. In terms of profitability, LGND's ROE is +0.16%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, LGND is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
LGND vs ABCM Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, LGND's ROE is +0.16%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, LGND is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
LGND vs ISEE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ISEE's P/E ratio is -22.44. In terms of profitability, LGND's ROE is +0.16%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, LGND is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
LGND vs APLS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas APLS's P/E ratio is 38.35. In terms of profitability, LGND's ROE is +0.16%, compared to APLS's ROE of +0.40%. Regarding short-term risk, LGND is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for LGND.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
LGND vs TVTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas TVTX's P/E ratio is -254.05. In terms of profitability, LGND's ROE is +0.16%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, LGND is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
LGND vs TERN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas TERN's P/E ratio is -51.41. In terms of profitability, LGND's ROE is +0.16%, compared to TERN's ROE of -0.20%. Regarding short-term risk, LGND is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
LGND vs DFTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas DFTX's P/E ratio is N/A. In terms of profitability, LGND's ROE is +0.16%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, LGND is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
LGND vs DYN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas DYN's P/E ratio is -7.82. In terms of profitability, LGND's ROE is +0.16%, compared to DYN's ROE of -0.64%. Regarding short-term risk, LGND is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for LGND.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
LGND vs CRSP Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CRSP's P/E ratio is -9.39. In terms of profitability, LGND's ROE is +0.16%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, LGND is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
LGND vs FOLD Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas FOLD's P/E ratio is -161.00. In terms of profitability, LGND's ROE is +0.16%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, LGND is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for LGND.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
LGND vs AKRO Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas AKRO's P/E ratio is -14.57. In terms of profitability, LGND's ROE is +0.16%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, LGND is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for LGND.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
LGND vs DNTH Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas DNTH's P/E ratio is -25.89. In terms of profitability, LGND's ROE is +0.16%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, LGND is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for LGND.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
LGND vs ALPN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ALPN's P/E ratio is -101.52. In terms of profitability, LGND's ROE is +0.16%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, LGND is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
LGND vs ACAD Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ACAD's P/E ratio is 12.68. In terms of profitability, LGND's ROE is +0.16%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, LGND is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
LGND vs CAI Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CAI's P/E ratio is -86.19. In terms of profitability, LGND's ROE is +0.16%, compared to CAI's ROE of +0.06%. Regarding short-term risk, LGND is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for LGND.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
LGND vs MANE Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MANE's P/E ratio is -33.36. In terms of profitability, LGND's ROE is +0.16%, compared to MANE's ROE of -0.84%. Regarding short-term risk, LGND is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for LGND.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
LGND vs OPT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas OPT's P/E ratio is -1.52. In terms of profitability, LGND's ROE is +0.16%, compared to OPT's ROE of +1.18%. Regarding short-term risk, LGND is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for LGND.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
LGND vs PRTC Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas PRTC's P/E ratio is -3.78. In terms of profitability, LGND's ROE is +0.16%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, LGND is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for LGND.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
LGND vs CELC Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CELC's P/E ratio is -22.15. In terms of profitability, LGND's ROE is +0.16%, compared to CELC's ROE of -2.45%. Regarding short-term risk, LGND is more volatile compared to CELC. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
LGND vs EWTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas EWTX's P/E ratio is -23.15. In terms of profitability, LGND's ROE is +0.16%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, LGND is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
LGND vs MRTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas MRTX's P/E ratio is -4.82. In terms of profitability, LGND's ROE is +0.16%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, LGND is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
LGND vs ELVN Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ELVN's P/E ratio is -32.82. In terms of profitability, LGND's ROE is +0.16%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, LGND is more volatile compared to ELVN. This indicates higher risk in terms of short-term price fluctuations for LGND.Check ELVN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
LGND vs CPRX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CPRX's P/E ratio is 12.30. In terms of profitability, LGND's ROE is +0.16%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, LGND is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CPRX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
LGND vs RYZB Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RYZB's P/E ratio is -57.86. In terms of profitability, LGND's ROE is +0.16%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, LGND is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
LGND vs CBAY Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas CBAY's P/E ratio is -32.81. In terms of profitability, LGND's ROE is +0.16%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, LGND is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for LGND.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
LGND vs VKTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas VKTX's P/E ratio is -7.67. In terms of profitability, LGND's ROE is +0.16%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, LGND is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for LGND.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
LGND vs DNLI Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas DNLI's P/E ratio is -7.99. In terms of profitability, LGND's ROE is +0.16%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, LGND is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for LGND.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
LGND vs ORKA Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ORKA's P/E ratio is -49.75. In terms of profitability, LGND's ROE is +0.16%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, LGND is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
LGND vs ADPT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ADPT's P/E ratio is -41.80. In terms of profitability, LGND's ROE is +0.16%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, LGND is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
LGND vs ALMS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ALMS's P/E ratio is -7.39. In terms of profitability, LGND's ROE is +0.16%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, LGND is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
LGND vs RCUS Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas RCUS's P/E ratio is -8.66. In terms of profitability, LGND's ROE is +0.16%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, LGND is more volatile compared to RCUS. This indicates higher risk in terms of short-term price fluctuations for LGND.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
LGND vs SWTX Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas SWTX's P/E ratio is -13.78. In terms of profitability, LGND's ROE is +0.16%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, LGND is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for LGND.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
LGND vs ARQT Comparison August 2026
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, LGND stands at 5.8B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, LGND is priced at $287.54 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
LGND currently has a P/E ratio of 34.48, whereas ARQT's P/E ratio is -933.00. In terms of profitability, LGND's ROE is +0.16%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, LGND is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for LGND.Check ARQT's competition here